VRTXVertex Pharmaceuticals
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. 10-K, Item 1
- Employees
- 6,400
- Headquarters
- Boston, MA
- CEO
- Reshma Kewalramani
- Next results
- around Feb 11, 2027
The biggest changes in the 10-K filed 2026-02-13, this fiscal year against the last, and the sentences in the MD&A (Item 7) where management explains them, quoted word for word. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
-2.1% → 34.8% (+36.9 pts) Big change FY to 2025-12-31 vs 2024-12-31“Selling, general and administrative expenses increased by 20% in 2025 as compared to 2024, primarily due to increased”
Read it in the 10-K ↗
Revenue
+8.9% FY to 2025-12-31 vs 2024-12-31“In 2025, our net product revenues increased $950.5 million, or 9%, as compared to 2024, primarily due to continued”
Read it in the 10-K ↗
“Our U.S. total revenues increased 13% in 2025, as compared to 2024, due to continued strong patient demand, new”
Read it in the 10-K ↗
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K ↗
Work on VRTX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.